Intabio is a Newark, Calif.-based developer of instrumentation systems for biotherapeutic precision analysis and quality assessment throughout bioproduction. Led by CEO and co-founder Lena Wu, Ph.D., the company is developing analytical solutions to facilitate biotherapeutic development and manufacturing, aiming to provide early product quality characterization and efficiency gains across all stages of biopharmaceutical development and manufacturing. Its first product, the Blaze system, is a microchip-based instrument that provides rapid detection and identification of subtle protein modifications that can undermine the stability and efficacy of biotherapeutic drugs such as monoclonal antibodies and recombinant proteins. Intabio raised $18M in a Series B financing. The company intends to use the funds to build its commercial team and prepare for launch of the platform. Intabio was launched in 2016 by CEO Lena Wu, Ph.D., and is based in Newark, CA. The company offers Blaze™, a microchip-based instrument platform for comprehensive analysis of antibody and protein biopharmaceutical products. Blaze is designed to deliver higher throughput than traditional methods and to provide rapid detection and identification of subtle protein modifications. Those subtle modifications can undermine the stability and efficacy of biotherapeutic drugs such as monoclonal antibodies and recombinant proteins. Financially, Intabio completed a $3.2M Series Seed in 2017 and has since raised a $9.5M Series A. The Series A included board appointments from investors, reflecting continued investor engagement. Intabio, based in Sunnyvale, develops instrumentation to accelerate biotherapeutic drug development. The company is commercializing the Blaze™ system, a bench-top instrument paired with a microfluidic chip and reagent kit that rapidly detects and identifies subtle protein modifications. Blaze performs charge heterogeneity analysis to separate protein isoforms, images at 280 nm for quantitation, and prepares samples for electrospray delivery into an adjacent mass spectrometer to identify unknown modifications. Leadership includes CEO and co-founder Lena Wu, Ph.D., and CTO and inventor Erik Gentalen. Intabio intends to use the financing to advance commercialization of its quality characterization system for biotherapeutics. Dr. Bill Hyun joined the company as a technical advisor.

Total raised

$30M

Funding rounds

3

Latest round

Series B

Latest activity

Feb 2020